G. Little
Queen Elizabeth College, Mauritius
6 Papers
46 Citations
G. Little is an academic researcher from Queen Elizabeth College, Mauritius. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Solubility of plant invertases
G. Little,J. Edelman +1 more
TL;DR: Solubilization of acid invertase associated with cell wall preparations from aged slices of Jerusalem artichoke tuber tissue was achieved at high ionic levels.
46
Prophylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD mice
Adrian L. Oblak,Zackary A. Cope,Sara K. Quinney,Ravi S. Pandey,Carla Biesdorf,Andrea R. Masters,Kristen D. Onos,Leslie Haynes,Kelly J. Keezer,Jill A. Meyer,Jonathan S. Peters,Scott A. Persohn,Amanda A. Bedwell,Kierra Eldridge,Rachael Speedy,G. Little,Sean‐Paul Williams,Brenda P. Noarbe,Andre Obenaus,Michael Sasner,Gareth R. Howell,Gregory T. Carter,Harriet M. Williams,Bruce T. Lamb,Paul R. Territo,Stacey J. Sukoff Rizzo +25 more
TL;DR: Prophylactic treatment of the BACE inhibitor verubecestat resulted in attenuated amyloid plaque deposition when treatment was initiated prior to significant pathology in 5XFAD mice, demonstrating the rigorous translational approaches of the MODEL‐AD PTC for interrogating potential therapeutics.
Aging × Genetics × Environment: Characterization of Precision Disease Models for Preclinical Testing for Late‐onset Alzheimer’s disease
Stacey J. Sukoff Rizzo,Katy A Haynes,Diogo Francisco S. Santos,Suzanne Doolen,G. Little,Aman Reddy,Nicholas Heaton,Jason T Hart,Michael Sasner,Kevin P. Kotredes,Dylan Garceau,Cynthia M. Ingraham,Ravi S. Pandey,Christoph Preuss,Asli Uyar,Nicholas T. Seyfried,Paul R. Territo,Gareth R. Howell,Gregory W. Carter,Adrian L. Oblak,Bruce T. Lamb +20 more
- 01 Dec 2023
TL;DR: Late-onset Alzheimer's disease (LOAD) models that recapitulate the complexity of the disease in human subjects are urgently needed to advance preclinical testing.
1
Pharmacodynamics Assessment of Aducanumab in 5XFAD mice: A MODEL‐AD PTC Study
Paul R. Territo,Sara K. Quinney,Andrea R. Masters,Katy A Haynes,Zackery A Cope,G. Little,Sean‐Paul Williams,Jill A. Meyer,Jonathan S. Peters,Lucas L. Figueiredo,Scott C. Persohn,Amanda A. Bedwell,Kierra Eldridge,Rachael Speedy,Nicholas T. Seyfried,Kristen D. Onos,Michael Sasner,Gareth R. Howell,Gregory T. Carter,Adrian L. Oblak,Bruce T. Lamb,Stacey J. Sukoff Rizzo +21 more
- 01 Dec 2022
TL;DR: The preclinical testing core (PTC) of the Model Organism Development for Evaluation of Late Onset Alzheimer's Disease (MODELAD) consortium established a rigorous preclinical drug testing strategy with go/no-go decision points that permits unbiased assessments of therapeutic agents as discussed by the authors .
1
Drug Development.
Kathryn A Haynes,Zackery A Cope,Sean‐Paul Williams,Umesh Nepali,G. Little,Suzanne Doolen,Emma Doud,Lais da Silva,Sara K. Quinney,Kierra Eldridge,Charles P. Burton,S. Persohn,Ravi S. Pandey,Gregory W. Carter,Michael Sasner,Bruce T. Lamb,Adrian L. Oblak,Paul R. Territo,Stacey J. Sukoff Rizzo +18 more